Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (26607)	11/18/1998 10:48:00 AM
From: celeryroot.com	Read Replies (2) \| Respond to of 32384

Unfortunatly that it is not the way it works. One does not look over the FDA's shoulder. A company is at the mercy of the FDA, which is understaffed and prone to delays. Ligand or any other organization does not set the schedule the FDA does. At this point all Ligand can do is wait for a response from the FDA and if asked for info respond quickly. There are many articles available which are highly critical of the FDA and explain the frustration of the drug firms. It has gotten better in the last 2 years due to new regulations . I suggest you look at the long dragged out saga of Chir/Ceph in getting Myo. approved.